Literature DB >> 32786924

Thermal Control of Engineered T-cells.

Mohamad H Abedi, Justin Lee, Dan I Piraner, Mikhail G Shapiro.   

Abstract

Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37-42 °C, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the activity of T-cells after they are deployed inside the body.

Entities:  

Keywords:  CAR; T-cells; heat shock promoters; immunotherapy; mammalian synthetic biology; thermal control

Mesh:

Substances:

Year:  2020        PMID: 32786924     DOI: 10.1021/acssynbio.0c00238

Source DB:  PubMed          Journal:  ACS Synth Biol        ISSN: 2161-5063            Impact factor:   5.110


  9 in total

Review 1.  Engineering living therapeutics with synthetic biology.

Authors:  Andres Cubillos-Ruiz; Tingxi Guo; Anna Sokolovska; Paul F Miller; James J Collins; Timothy K Lu; Jose M Lora
Journal:  Nat Rev Drug Discov       Date:  2021-10-06       Impact factor: 84.694

Review 2.  Engineering the next generation of cell-based therapeutics.

Authors:  Caleb J Bashor; Isaac B Hilton; Hozefa Bandukwala; Devyn M Smith; Omid Veiseh
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

3.  Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control.

Authors:  Ian C Miller; Ali Zamat; Lee-Kai Sun; Hathaichanok Phuengkham; Adrian M Harris; Lena Gamboa; Jason Yang; John P Murad; Saul J Priceman; Gabriel A Kwong
Journal:  Nat Biomed Eng       Date:  2021-08-12       Impact factor: 25.671

Review 4.  The evolution of synthetic receptor systems.

Authors:  Janvie Manhas; Hailey I Edelstein; Joshua N Leonard; Leonardo Morsut
Journal:  Nat Chem Biol       Date:  2022-01-20       Impact factor: 16.174

5.  Reversible thermal regulation for bifunctional dynamic control of gene expression in Escherichia coli.

Authors:  Xuan Wang; Jia-Ning Han; Xu Zhang; Yue-Yuan Ma; Yina Lin; Huan Wang; Dian-Jie Li; Tao-Ran Zheng; Fu-Qing Wu; Jian-Wen Ye; Guo-Qiang Chen
Journal:  Nat Commun       Date:  2021-03-03       Impact factor: 14.919

Review 6.  Heat Shock Proteins in Lymphoma Immunotherapy.

Authors:  Zarema Albakova; Yana Mangasarova; Alexander Sapozhnikov
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

7.  Genetically Encoded Protein Thermometer Enables Precise Electrothermal Control of Transgene Expression.

Authors:  Bozhidar-Adrian Stefanov; Ana P Teixeira; Maysam Mansouri; Adrian Bertschi; Krzysztof Krawczyk; Ghislaine Charpin-El Hamri; Shuai Xue; Martin Fussenegger
Journal:  Adv Sci (Weinh)       Date:  2021-09-08       Impact factor: 16.806

8.  Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy.

Authors:  Yuhao Chen; Meng Du; Zhen Yuan; Zhiyi Chen; Fei Yan
Journal:  Nat Commun       Date:  2022-08-02       Impact factor: 17.694

9.  Ultrasound-controllable engineered bacteria for cancer immunotherapy.

Authors:  Mohamad H Abedi; Michael S Yao; David R Mittelstein; Avinoam Bar-Zion; Margaret B Swift; Audrey Lee-Gosselin; Pierina Barturen-Larrea; Marjorie T Buss; Mikhail G Shapiro
Journal:  Nat Commun       Date:  2022-03-24       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.